# US 7,745,121 B2 · Polymorphism in the macrophage migration inhibitory factor (MIF) gene as marker for prostate cancer

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 7,745,121 B2
- Document ID: US7745121B2
- Status: Granted
- Kind: B2
- Application number: 11/438,370
- Filed: 2006-05-23
- Published: 2007-03-01
- Granted: 2010-06-29
- Earliest claimed: 2005-05-23
- Assignees: Department of Veterans Affairs
- Inventors: Katherine Siegler; Kenneth Iczkowski; Richard Bucala; Pedro L. Vera
- Web page: https://patentgrep.com/patent/US7745121B2

## CPC

- C12Q 1/6886: for cancer (immunoassay for cancer G01N33/575)
- C12Q 2600/118: Prognosis of disease development
- C12Q 2600/136: Screening for pharmacological compounds
- C12Q 2600/156: Polymorphic or mutational markers
- C12Q 2600/172: Haplotypes
- C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES

## Abstract

The present invention relates to the risk assessment, detection, diagnosis, or prognosis of prostate cancer. More specifically, this invention relates to the detection of certain polymorphism in the promoter region of the MIF gene to determine the risk, detect, diagnose, or prognosticate prostate cancer. Applicants have discovered that the presence of a −173C and/or −749 (CATT)7 or more repeat predispose an individual to prostate cancer.

## Claims

### Claim 1

A method for determining the risk of, detecting, diagnosing, or prognosticating prostate cancer in an individual, comprising the steps of testing the individual for the presence of a −173 C mutation or a CATT repeat in the promoter of the macrophage migration inhibitory factor (MIF) gene, wherein the CATT repeat is 7 or higher repeats locating at position −749, and wherein the testing step comprises
a) collecting a nucleic acid sample from the individual;
b) amplifying the nucleic acid sample; and
c) sequencing the promoter of the MIF gene.

### Claim 2 (depends on 1)

The method of claim 1, wherein the promoter of the MIF gene has the nucleotide sequence of nucleotides 1 to 1263 of SEQ ID NO: 1.

### Claim 3 (depends on 1)

The method of claim 1, wherein the nucleic acid is DNA.

### Claim 4 (depends on 1)

The method of claim 1, further comprising the step of determining the amount of prostate specific antigen in the individual.

### Claim 5 (depends on 1)

The method of claim 1, wherein the CATT repeat is (CATT)7.